| 1. |
Phase III HIV-1 vaccine trials require better rationale |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1423,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
The US CDC*and the WHO are collaborating to produce an avian flu vaccine using reverse genetics, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1423,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
DoesH. pylorieradication exacerbate GERD? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1423,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Anastrozole and exemestane best bets for metastatic breast cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1423,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Tesmilifene beneficial in advanced breast cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1423,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
ABI 007 an advance on paclitaxel in metastatic breast cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1423,
2004,
Page 7-8
K McRae,,
Preview
|
|
摘要:
ABI 007 [Abraxane], a nanoparticle albumin-bound (nab) formulation of paclitaxel, demonstrated efficacy superior to that of standard solvent-based paclitaxel [Taxol] in patients with metastatic breast cancer in a head-to-head comparative study. Data from this study were presented in a late-breaker session at the 26th San Antonio Breast Cancer Symposium (SABCS) [San Antonio, US; December 2003] by Dr Joyce O'Shaughnessy from the Baylor-Charles A. Sammons Cancer Center, US Oncology, Dallas, US. The study results showed that overall response rates and time to tumour progression were significantly increased in patients treated with ABI 007, compared with paclitaxel recipients. Importantly, although they did not receive routine concomitant corticosteroids for hypersensitivity prophylaxis, patients treated with ABI 007 experienced significantly less hypersensitivity and flushing than paclitaxel recipients who did receive concomitant corticosteroids.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Topical nitroglycerin 0.4% [Cellegesic; Cellegy Pharmaceuticals] successfully treats chronic anal fissure pain, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1423,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
IV valproic acid reduces headache pain in patients with moderate-to-severe headache or migraine, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1423,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Protease inhibitor-based triple regimens: superior HIV therapy |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1423,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Neoadjuvant anastrozole has impact on mastectomy rates |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1423,
2004,
Page 13-14
K McRae,,
Preview
|
|
摘要:
Neoadjuvant treatment with anastrozole [Arimidex] reduces the need for mastectomy in postmenopausal women with operable hormone receptor-positive breast cancer, compared with tamoxifen, according to results from the IMPACT1 study presented at the 26th annual San Antonio Breast Cancer Symposium (SABCS) [San Antonio, US; December 2003]. After 3 months, women treated with anastrozole were twice as likely as those treated with tamoxifen to have their tumour downstaged, allowing breast-conserving surgery to be performed. Combination therapy with anastrozole plus tamoxifen demonstrated efficacy similar to that of tamoxifen alone. There were no significant differences between the three treatment groups with respect to objective response rates, although a trend favouring anastrozole was observed among patients with HER2+ cancers.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
